<DOC>
	<DOCNO>NCT01368081</DOCNO>
	<brief_summary>The objective study investigate long-term safety efficacy BI 10773 give 52 week add-on therapy one oral antidiabetic drug patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Empagliflozin ( BI 10773 ) Comprehensive add-on Study Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : .Diagnosis type 2 diabetes mellitus prior inform consent Male female patient , diet exercise regimen , pretreated one follow oral antidiabetic drug : sulfonylurea , glinide , biguanide , Alphaglucosidase inhibitor ( aGI ) , dipeptidyl peptidaseIV ( DPPIV ) inhibitor thiazolidinedione glycosylated haemoglobin ( HbA1c ) Visit 1 : &gt; =7.0 = &lt; 10.0 % ( national glycohemoglobin standardization program ) Exclusion criterion : Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dL ( &gt; 13.3 mmol/L ) Acute coronary syndrome , stroke transient ischemic attack ( TIA ) within 12 week prior inform consent Indication liver disease , define serum level either alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase ( ALP ) 3 x upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>